Scholarlink

Background <p>The Stupp protocol standardized adjuvant radiotherapy (RT) with temozolomide as the best treatment after glioblastoma (GBM) resection. Later phase III trials found that moderate hypofractionation and ultrahypofractionation were not inferior in elderly or frail patients. As most recurrences occurred near the tumor bed, RT margins could be reduced, favoring ultrahypofractionated RT (UHRT). Neoadjuvant UHRT might provide additional benefits by allowing better margin selection and lowering radionecrosis risk through the surgical removal of the irradiated tissue.</p> Methods <p>This is a phase I, single-arm, multicenter clinical trial having as primary endpoint the identification of maximum tolerated dose in operable GBM patients. A total dose of 30&#xa0;Gy delivered in 5 fractions will be prescribed to planning target volume, with a simultaneous integrated boost dose escalation to gross tumor volume from 35 to 50&#xa0;Gy, with 5 patients at each dose level. Dose to the next patient group will be escalated if toxicity target is met. The assumption is that not more than 30% of patients would present cumulative ≥G3 toxicity (CTCAE v5.0 scale) one month after the end of UHRT. A 30-patient sample size is predicted to result in a 2-sided 95% confidence interval with a width of 0.328 (0.136–0.464) when the sample proportion is 0.300. Four weeks after the end of UHRT, following a brain MRI, the lesion will be surgically removed. A peripheral blood sample will be taken before and after UHRT, up to 6 months, for immunophenotyping.</p> Discussion <p>The study aims at evaluating MRI-guided dose escalation neoadjuvant UHRT-related toxicity along with potential improvements in overall- and disease-free survival. Other goals are to identify prognostic factors and monitor radiation-treatment related immune effects. An important expected benefit of the neoadjuvant UHRT is that it will shorten treatment time, improving patients’ quality of life, and facilitate access to specialized treatment centers. Neoadjuvant RT represents a paradigm shift in GBM, and implications for the scientific community should be significant. The study may help identify distribution patterns of aggressive radioresistant areas with a higher probability of recurrence, counteract intrinsic radioresistance, and identify immune correlates of therapeutic efficacy and/or biomarkers of treatment response/toxicity.</p> Trial registration <p>The study was prospectively registered at clinicaltrials.gov (NCT06551909, 13/08/2024). Protocol version: Version 1.0, 17/06/2024.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoadjuvant ultrahypofractionated radiotherapy with simultaneous integrated boost for glioblastoma: study protocol for a phase I multicenter clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月6日

查看全文
  • Nadia Di Muzio,
  • Miriam Torrisi,
  • Raffaella Barzaghi,
  • Arianna Pocaterra,
  • Martina Mori,
  • Filippo Folchini,
  • Laura Giannini,
  • Micol Valle,
  • Michele Bailo,
  • Chiara Lucrezia Deantoni,
  • Silvia Snider,
  • Filippo Gagliardi,
  • Eliana Ruggiero,
  • Sara Broggi,
  • Luca Ruffino,
  • Rossella Di Franco,
  • Simona Mercogliano,
  • Claudio Fiorino,
  • Antonella Del Vecchio,
  • Matteo Muto,
  • Paolo Muto,
  • Pietro Mortini,
  • Anna Mondino,
  • Andrei Fodor

摘要

Background

The Stupp protocol standardized adjuvant radiotherapy (RT) with temozolomide as the best treatment after glioblastoma (GBM) resection. Later phase III trials found that moderate hypofractionation and ultrahypofractionation were not inferior in elderly or frail patients. As most recurrences occurred near the tumor bed, RT margins could be reduced, favoring ultrahypofractionated RT (UHRT). Neoadjuvant UHRT might provide additional benefits by allowing better margin selection and lowering radionecrosis risk through the surgical removal of the irradiated tissue.

Methods

This is a phase I, single-arm, multicenter clinical trial having as primary endpoint the identification of maximum tolerated dose in operable GBM patients. A total dose of 30 Gy delivered in 5 fractions will be prescribed to planning target volume, with a simultaneous integrated boost dose escalation to gross tumor volume from 35 to 50 Gy, with 5 patients at each dose level. Dose to the next patient group will be escalated if toxicity target is met. The assumption is that not more than 30% of patients would present cumulative ≥G3 toxicity (CTCAE v5.0 scale) one month after the end of UHRT. A 30-patient sample size is predicted to result in a 2-sided 95% confidence interval with a width of 0.328 (0.136–0.464) when the sample proportion is 0.300. Four weeks after the end of UHRT, following a brain MRI, the lesion will be surgically removed. A peripheral blood sample will be taken before and after UHRT, up to 6 months, for immunophenotyping.

Discussion

The study aims at evaluating MRI-guided dose escalation neoadjuvant UHRT-related toxicity along with potential improvements in overall- and disease-free survival. Other goals are to identify prognostic factors and monitor radiation-treatment related immune effects. An important expected benefit of the neoadjuvant UHRT is that it will shorten treatment time, improving patients’ quality of life, and facilitate access to specialized treatment centers. Neoadjuvant RT represents a paradigm shift in GBM, and implications for the scientific community should be significant. The study may help identify distribution patterns of aggressive radioresistant areas with a higher probability of recurrence, counteract intrinsic radioresistance, and identify immune correlates of therapeutic efficacy and/or biomarkers of treatment response/toxicity.

Trial registration

The study was prospectively registered at clinicaltrials.gov (NCT06551909, 13/08/2024). Protocol version: Version 1.0, 17/06/2024.